Global glaucoma market is projected to witness a CAGR of 5.15% during the forecast period 2024-2031, growing from USD 8.53 billion in 2023 to USD 12.75 billion in 2031. The market demand for glaucoma treatment is anticipated to thrive drastically in the forecast years due to rising prevalence and the growing interest of investors and market players.
Glaucoma is a group of eye conditions that affect the optic nerve. This optic nerve transmits visual information from your eye to your brain and is quintessential for good vision. Glaucoma is usually associated with damage to the optic nerve, often due to high pressure inside the eye, though it can occur with normal eye pressure. Glaucoma can be present at any age but occurs more often with advancing age. It is one of the major causes of blindness in patients older than 60 years of age. The symptoms of glaucoma are based on the type and stage of your condition. The most common type of glaucoma is open-angle glaucoma and other types are less common, like angle-closure glaucoma. Open-angle glaucoma shows no symptoms in early stage, just patchy blind spot in side vision. Acute angle-closure glaucoma symptoms are severe headache, blurred vision, eye redness, severe eye pain, nausea and vomiting. At present, there are 80 million people worldwide affected with glaucoma. More than 3 million Americans are affected with glaucoma; of these, 2.7 million (aged 40 and older) have its most common type, open-angle glaucoma. As per the report published in June 2023, by Glaucoma Journal, it is estimated that by 2040, there will be 22 million blind people around the world affected with glaucoma. The World Glaucoma Week is an international initiative organized by the World Glaucoma Association. They invite patients, eye care providers, health officials, and the community to partner together in planning advocacy activities globally. Glaucoma is the leading cause of preventable blindness, and unique challenges exist in various parts of the world. The goal here is to enlighten everyone to check their eyes and optic nerves regularly so that glaucoma can be detected as early as possible and treatment can begin to prevent vision loss.
Rising Prevalence of Glaucoma Disease
The increasing prevalence of glaucoma also poses public health concerns for reasons other than the aging global population. It is a leading cause of irreversible blindness, and its prevalence is expected to soar in the future. Factors involved include aging demographics – for example, an increasing population older than 60 years and the risk of developing glaucoma increases with age. In addition, increased knowledge and changes in the methods of diagnosis have led to a higher detection of the disease, which underlines the prevalence of the disease. Socioeconomic factors such as urbanization also play a key role. They can aggravate risk factors like hypertension and diabetes associated with glaucoma. Consequently, the control of the rising prevalence of the disease constitutes a significant aspect of public health efforts and healthcare systems in the worldr. For instance, on 22 September 2022, Santen and UBE announced the Food and Drug Administration approval for Omlonti (omidenepag isopropyl ophthalmic solution) 0.002% eye drops for the reduction of intraocular pressure in adults with open-angle glaucoma or ocular hypertension. Omlonti, the active pharmaceutical ingredient is omidenepag isopropyl, which is a relatively selective prostaglandin EP2 receptor agonist that increases aqueous humor drainage through the conventional (or trabecular) and uveoscleral outflow pathways.
Increasing Awareness and Advancement in Technology Brings Glaucoma Market Growth
Advanced treatments for glaucoma have dramatically changed the treatment of the disease, offering patients much more effective and targeted alternative therapies. Some of the recent innovations in pharmacotherapy involve entirely new classes of drugs, such as Rho kinase inhibitors, which represent an alternative means of lowering intraocular pressure. In addition, sustained-release drug delivery systems and implantable devices offer a degree of increased consistency with regard to adherence to any prescribed medication regimen and decreased side effects. Less-invasive surgical techniques, especially microinvasive glaucoma surgery (MIGS), have proven effective in the management of glaucoma with less time to recover and reduced morbidity compared with conventional surgeries. Such developments not only improve patient outcomes but also bring up the quality of life in patients suffering from the disease, thus making it crucial to continue further research and development work in this most critical area of eye care. For instance, in May 2024, Lupin Global, a pharmaceutical giant got approval from the United States Food and Drug Administration (US FDA) for its Abbreviated New Drug Application (ANDA) for travoprost ophthalmic solution USP, 0.004% (ionic buffered solution). Travoprost ophthalmic solution USP, 0.004%, is indicated for lowering of intraocular pressure in patients diagnosed with open-angle glaucoma or ocular hypertension.
Rising Prevalence of Open Angle Glaucoma Segment to Dominate the Glaucoma Market
Open-angle glaucoma is expected to be a key driver for growth in this market in the face of the increasing incidence of open-angle glaucoma. Open Angle Glaucoma is the most common type of glaucoma and usually lacks symptoms in the early stages, thereby developing an increasing population that is untreated and undiagnosed as awareness increases. This is highly significant within aging populations, since the incidence of eye diseases is more prevalent within such populations. Advancements in diagnostic technologies and treatments, such as topical medications and surgical interventions, will continue to fuel further growth in the market. A focus on early detection and management of Open Angle Glaucoma to prevent vision loss is further likely to invest research and development efforts as well as increase patient education – which will have a positive impact on the market dynamics anticipated to rise in the future due to improved diagnostics facilities which enable more patients to be treated promptly. For instance, on 14 December 2022, Thea Pharma, Inc., the U.S. subsidiary of Europe’s leading independent pharmaceutical company, announced the U.S. Food and Drug Administration (FDA) approval for the New Drug Application (NDA) of IYUZEH (latanoprost ophthalmic solution) 0.005% for the reduction of elevated intraocular pressure (IOP) in patients with open-angle glaucoma (OAG) or ocular hypertension (OHT).
North America Dominates the Glaucoma Market
North America currently dominates the glaucoma market, driven by a combination of advanced healthcare infrastructure, high awareness of eye health. Glaucoma is one of the major causes of irreversible blindness in the United States. More than 3 million Americans suffer from glaucoma. It is expected that by 2050, this number will increase to 6.3 million because of the aging US population. Glaucoma costs the US economy USD 2.86 billion every year through direct costs and loss of productivity. This region has a highly integrated network of ophthalmologists and eye care specialists that helps patients have proper treatment options at the right time. In terms of government initiatives and collaboration by private sectors, advanced treatments will be accessible. Robust reimbursement policies also sustain good care for patients. North America is likely to continue at the top, with its contribution expected to play a huge role in ongoing developments and new approaches for the prevention and management of glaucoma. For instance, on 15 December 2023, the United States Food and Drug Administration approved a new treatment for glaucoma, iDose TR (travoprost intracameral implant, 75 mcg). The new iDose TR is the first and only device of its kind that is specifically developed to offer up to three years of 24/7, continuous drug therapy directly inside the eye, helping patients suffering with glaucoma take control of the elevated eye pressure associated with this vision disease.
Future Market Scenario (2024-2031F)
The future market scenario for the glaucoma market appears promising and is characterized by significant advancements in technology and treatment options. The future of glaucoma management will change dramatically with emerging novel therapies, such as neuroprotective agents and minimally invasive surgical techniques. Ideally, telemedicine and other digital health solutions are expected to come in, making it easier for patients to adhere and monitor themselves. Moreover, increasing awareness and education will continue to result in earlier diagnoses. As a result, the prevalence of vision loss is likely to decrease. In addition, the increasing global demographics and an ageing population around the world will also increase demand for effective glaucoma treatments, resulting in significant demand and investment in the sector. For instance, sustained-release glaucoma drug delivery systems are currently being developed or are in the pipeline. Latanoprost punctal plug delivery system L-PPDS (Evolute, Mati Therapeutics, Austin, TX, USA) is a punctal plug loaded with prostaglandin analogs, it is currently in Phase II clinical trial.
Report Scope
“Glaucoma Market Assessment, Opportunities and Forecast, 2017-2031F”, is a comprehensive report by Markets and Data, providing in-depth analysis and qualitative and quantitative assessment of the current state of global glaucoma market, industry dynamics, and challenges. The report includes market size, segmental shares, growth trends, opportunities, and forecast between 2024 and 2031. Additionally, the report profiles the leading players in the industry, mentioning their respective market share, business models, competitive intelligence, etc.
Click Here:https://www.marketsandata.com/industry-reports/glaucoma-market
About Us:
Markets and Data provides a comprehensive/ panoramic understanding of markets at global, regional, and country levels. Examine changing consumer preferences, emerging challenges, underlying trends, and growth prospects to accelerate your business strategies.
Contact
Mr. Vivek Gupta
5741 Cleveland street,
Suite 120, VA beach, VA, USA 23462
Tel: +1 (757) 343-3258
Email: info@marketsandata.com
Website: https://www.marketsandata.com